Skip to main content
SpringerLink
Log in

Epigenetic inhibition of lysyl oxidase transcription after transformation by ras oncogene

  • Published:
Molecular and Cellular Biochemistry Aims and scope Submit manuscript

Abstract

Lysyl oxidase is an extracellular enzyme involved in connective tissue maturation that also acts as a phenotypic suppressor of the ras oncogene. To understand how this suppressor is controlled, gene transcription was studied and the promoter was characterized. Nuclear runoff transcription assays indicated that the markedly reduced amounts of lysyl oxidase message detected after ras transformation resulted from inhibition of lysyl oxidase transcription. Interferon-mediated phenotypic reversion of ras transformed cells, in which the ras oncogene continued to be expressed, was accompanied by the restoration of lysyl oxidase transcription. Reporter gene assay of a transfected mouse lysyl oxidase promoter indicated that it was active in the transformed background, despite the silencing of the endogenous lysyl oxidase promoter. The detection of comparable amounts of mRNA for transcription factors IRF-1 and IRF-2 in normal and ras-transformed cell lines suggests that the differential transcription of lysyl oxidase was not due to regulation of IRFs. Lysyl oxidase promoter activity was localized to a 126 bp region that includes two consensus TATA boxes with associated confirmed cap signals. Analysis of a human lysyl oxidase promoter sequence indicated similar promoter elements and extensive sequence identity with the mouse promoter. The binding of transcription factor AP2 to sites predicted in the control region was confirmed by DNase footprinting. Lysyl oxidase transcription was stimulated by dexamethasone treatment of cells, but this effect could not be assigned within the ~3 kb region tested in reporter gene constructs. The promoter activity of the lysyl oxidase reporter gene construct was completely abolished by in vitro DNA methylation, suggesting that the transcriptional suppression after transformation by the ras oncogene may involve DNA methylation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Contente S, Kenyon K, Rimoldi D, Friedman RM: Expression of gene rrg is associated with reversion of NIH 3T3 transformed by LTR-c-Hras. Science 249: 796–798, 1990

    PubMed  Google Scholar 

  2. Kenyon K, Contente S, Trackman PC, Tang J, Kagan HM, Friedman RM: Lysyl oxidase and rrg messenger RNA. Science 253: 802, 1991

    PubMed  Google Scholar 

  3. Samid D, Chang EH, Friedman RM: Biochemical correlates of phenotypic reversion in interferon-treated mouse cells transformed by a human oncogene. Biochem Biophys Res Commun 119: 21–28, 1984

    PubMed  Google Scholar 

  4. Samid D, Chang EH, Friedman RM, Schaff Z, Greene JJ: Biological and morphological characteristics of phenotypic revertants appearing in interferon-treated mouse cells transformed by a human oncogene. J Exp Pathol 2: 211–222, 1985

    PubMed  Google Scholar 

  5. Samid D, Flessate DM, Friedman RM: Interferon-induced revertants of ras-transformed cells: Resistance to transformation by specific oncogenes and retransformation by 5-azacytidine. Mol Cell Biol 7: 2196–2200, 1987

    PubMed  Google Scholar 

  6. Pinnell SR, Martin GR: The cross-linking of collagen and elastin: Enzymatic conversion of lysine in peptide linkage to α-aminoadipic-δ-semialdehyde (allysine) by an extract from bone. Proc Natl Acad Sci USA 61: 708–716, 1968

    PubMed  Google Scholar 

  7. Krzyzosiak WJ, Shindo-Okada N, Teshima H, Nakajima K, Nishimura S: Isolation of genes specifically expressed in flat revertant cells derived from activated ras transformed NIH 3T3 cells by treatment with azatyrosine. Proc Natl Acad Sci USA 89: 4879–4883, 1992

    PubMed  Google Scholar 

  8. Hajnal, A, Klemenz, R and Schafer, R: Up-regulation of lysyl oxidase in spontaneous revertants of H-ras-transformed rat fibroblasts. Cancer Res 53: 4670–4675, 1993

    PubMed  Google Scholar 

  9. Shaefer R, Iyer J, Iten E, Nirkko A: Partial reversion of the transformed phenotype in HRAS-transfected tumorigenic cells by transfer of a human gene. Proc Natl Acad Sci USA 85: 1590–1594, 1988

    PubMed  Google Scholar 

  10. Oberhuber H, Seliger B, Schafer R: Partial restoration of pretransformation levels of lysyl oxidase and transin mRNAs in phenotypic ras revertants. Mol Carcinog 12: 198–204, 1995

    PubMed  Google Scholar 

  11. Seliger B, Pfizenmaier K, Schäfer R: Short-term treatment with gamma interferon induces stable reversion of ras-transformed mouse fibroblasts. J Virology 65: 6307–6311, 1991

    PubMed  Google Scholar 

  12. Contente S, Csiszar K, Kenyon K, Friedman RM: Structure of the mouse lysyl oxidase gene. Genomics 16: 395–400, 1993

    PubMed  Google Scholar 

  13. Tan RS, Taniguchi T, Harada H: Identification of the lysyl oxidase gene as target of the antioncogenic transcription factor, IRF-1, and its possible role in turnor suppression. Cancer Res 56: 2417–2421, 1996

    PubMed  Google Scholar 

  14. Rideout WM 3rd, Eversole-Cire P, Spruck CH 3rd, Hustad CM, Coetzee GA, Gonzales FA, Jones PA: Progressive increases in the methylation status and heterochromatinization of the myoD CpG island during oncogenic transformation. Mol Cell Biol 14: 6143–6152, 1994

    PubMed  Google Scholar 

  15. Sakai T, Toguchida J, Ohtani N, Yandell DW, Rapaport JM, Dryja TP: Allele specific hypermethylation of the retinoblastoma tumorsuppressor gene. Am J Hum Genet 48: 880–888, 1991

    PubMed  Google Scholar 

  16. Herman JG, Latif F, Weng Y, Lerman MI, Zbar B, Liu S, Samid D, Duan DS, Gnarra JR, Linehan WM, et al: Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci USA 91: 9700–9704, 1994

    PubMed  Google Scholar 

  17. Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC, Baylin SB, Sidransky D: 5′island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers [see comments]. Nat Med 1: 686–692, 1995

    PubMed  Google Scholar 

  18. Gonzalez-Zulueta M, Bender CM, Yang AS, Nguyen T, Beart RW, Van Tornout JM, Jones PA: Methylation of the 5′CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. Cancer Res 55: 4531–4535, 1995

    PubMed  Google Scholar 

  19. Yoshiura K, Kanai Y, Ochiai A, Shimoyama Y, Sugimura T, Hirohashi S: Silencing of the E-cadherin invasion-suppressor gene by CpG methylation in human carcinomas. Proc Natl Acad Sci USA 92: 7416–7419, 1995

    PubMed  Google Scholar 

  20. Kumar G: Two cat expression vectors for cloning and generation of 3′-and 5′-deletion mutants. Gene 110: 101–103, 1992

    PubMed  Google Scholar 

  21. Chang EH, Furth ME, Scolnick EM, Lowy DR: Tumorigenic transformation of mammalian cells induced by a normal human gene homologous to the oncogene of Harvey murine sarcoma virus. Nature 297: 479–483, 1982

    PubMed  Google Scholar 

  22. Greenberg ME, Bender TP: Identification of newly transcribed RNA. In: F.M. Ausubel, R. Brent, R.E. Kingston, D.D. Moore, J.G. Seidman, J.A. Smith, K. Struhl (eds), Current Protocols in Molecular Biology. John Wiley & Sons, New York, 1994, pp. 4.10.1–4.10.5.

    Google Scholar 

  23. Barber SA, Fultz MJ, Salkowski CA, Vogel SN: Differential expression of interferon regulatory factor 1 (IRF-1), IRF-2, and interferon consensus sequence binding protein genes in lipopolysaccharide (LPS)-responsive and LPS-hyporesponsive macrophages. Infect Immun 63: 601–608, 1995

    PubMed  Google Scholar 

  24. Pelle R, Murphy NB: Northern hybridization: Rapid and simple electrophoretic conditions. Nucleic Acids Res 21: 2783–2784, 1993

    PubMed  Google Scholar 

  25. Friedman RM, Yeh A, Gutman P, Contente S, Kenyon K: Reversion by deletion of transforming oncogene following interferon-beta and retinoic acid treatment. J Interferon Cytokine Res 17: 647–651, 1997

    PubMed  Google Scholar 

  26. Rimoldi D, Srikantan V, Wilson VL, Bassin RH, Samid D: Increased sensitivity of nontumorigenic fibroblasts expressing ras or myc oncogenes to malignant transformation induced by 5-Aza-2′-deoxycytidine. Cancer Res 51: 324–330, 1991

    PubMed  Google Scholar 

  27. Hamalainen ER, Kemppainen R, Kuivaniemi H, Tromp G, Vaheri A, Pihlajaniemi T, Kivirikko KI: Quantitative polymerase chain reaction of lysyl oxidase mRNA in malignantly transformed human cell lines demonstrates that their low lysyl oxidase activity is due to low quantities of its mRNA and low levels of transcription of the respective gene. J Biol Chem 270: 21590–21593, 1995

    PubMed  Google Scholar 

  28. Su Z-Z, Yemul S, Estabrook A, Friedman RM, Zimmer SG, Fisher PB: Transcriptional switching model for the regulation of tumorigenesis and metastasis by the Ha-ras oncogene: transcriptional changes in the Ha-ras tumor suppressor gene lysyl oxidase. Int J Oncol 7: 1279–1284, 1995

    Google Scholar 

  29. Harada H, Fujita T, Miyamoto M, Kimura Y, Maruyama M, Furia A, Miyata T, Taniguchi T: Structurally similar but functionally distinct factors, IRF-1 and IRF-2, bind to the same regulatory elements of IFN and IFN-inducible genes. Cell 58: 729–739, 1989

    Article  PubMed  Google Scholar 

  30. Harada H, Kitagawa M, Tanaka N, Yamamoto H, Harada K, Ishihara M, Taniguchi T: Anti-oncogenic and oncogenic potentials of interferon regulatory factors-1 and-2. Science 259: 971–974, 1993

    PubMed  Google Scholar 

  31. Schroeder M, Mass MJ: CpG methylation inactivates the transcriptional activity of the promoter of the human p53 tumor suppressor gene. Biochem Biophys Res Commun 235: 403–406, 1997

    PubMed  Google Scholar 

  32. Jourdan-Le Saux C, Gleyzal C, Raccurt, Sommer P: Functional analysis of the lysyl oxidase promoter in myofibroblast-like clones of 3T6 fibroblast. J Cell Biochem 64: 328–341, 1997

    PubMed  Google Scholar 

  33. Csiszar K, Entersz I, Trackman PC, Samid D, Boyd CD: Functional analysis of the promoter and first intron of the human lysyl oxidase gene. Mol Biol Rep 23: 97–108, 1996

    PubMed  Google Scholar 

  34. Counts DF, Shull S, Cutroneo KR: Skin lysyl oxidase activity is not rate limiting for collagen crosslinking in the glucocorticoid-treated rat. Connect Tissue Res 14: 237–243, 1986

    PubMed  Google Scholar 

  35. Ozasa H, Tominaga T, Nishimura T, Takeda T: Lysyl oxidase activity in the mouse uterine cervix is physiologically regulated by estrogen. Endocrinology 109: 618–621, 1981

    PubMed  Google Scholar 

  36. Ozasa H, Tominaga T, Takeda T: Evidence of an estrogen-like effect of dehydroepiandrosterone on lysyl oxidase activity in the mouse cervix. Acta Obstet Gynecol Scand 65: 543–545, 1986

    PubMed  Google Scholar 

  37. Bronson RE, Calaman SD, Traish AM, Kagan HM: Stimulation of lysyl oxidase (EC 1.4.3.13) activity by testosterone and characterization of androgen receptors in cultured calf aorta smooth-muscle cells. Biochem J 244: 317–323, 1987

    PubMed  Google Scholar 

  38. Lee GC, Yang IM, Kim BJ, Woo JT, Kim SW, Kim JW, Kim YS, Choi YK: Identification of glucocorticoid response element of the rat TRH gene. Korean J Intern Med 11: 138–144, 1996

    PubMed  Google Scholar 

  39. Schuetz JD, Schuetz EG, Thottassery JV, Guzelian PS, Strom S, Sun D: Identification of a novel dexamethasone responsive enhancer in the human CYP3A5 gene and its activation in human and rat liver cells. Mol Pharmacol 49: 63–72, 1996

    PubMed  Google Scholar 

  40. Del Monaco M, Covello SP, Kennedy SH, Gilinger G, Litwack G, Uitto J: Identification of novel glucocorticoid-response elements in human elastin promoter and demonstration of nucleotide sequence specificity of the receptor binding. J Invest Dermatol 108: 938–942, 1997

    PubMed  Google Scholar 

  41. Gacheru SN, Thomas KM, Murray SA, Csiszar K, Smith-Mungo LI, Kagan HM: Transcriptional and post-transcriptional control of lysyl oxidase expression in vascular smooth muscle cells: Effects of TGF-beta 1 and serum deprivation. J Cell Biochem 65: 395–407, 1997

    PubMed  Google Scholar 

  42. Wakasaki H, Ooshima A: Immunohistochemical localization of lysyl oxidase with monoclonal antibodies. Lab Invest 63: 377–384, 1990

    PubMed  Google Scholar 

  43. Kobayashi H, Ishii M, Chanoki M, Yashiro N, Fushida H, Fukai K, Kono T, Hamada T, Wakasaki H, Ooshima A: Immunohistochemical localization of lysyl oxidase in normal human skin. Br J Dermatol 131: 325–330, 1994

    PubMed  Google Scholar 

  44. Kagan HM, Williams MA, Calaman SD, Berkowitz EM: Histone HI is a substrate for lysyl oxidase and contains endogenous sodium borotritidereducible residues. Biochem Biophys Res Commun 115: 186–192, 1983

    PubMed  Google Scholar 

  45. Kagan HM, Williams MA, Williamson PR, Anderson JM: Influence of sequence and charge on the specificity of lysyl oxidase toward protein and synthetic peptide substrates. J Biol Chem 259: 11203–11207, 1984

    PubMed  Google Scholar 

  46. Li W, Nellaiappan K, Strassmaier T, Graham L, Thomas KM, Kagan HM: Localization and activity of lysyl oxidase within nuclei of fibrogenic cells. Proc Natl Acad Sci USA 94: 12817–12822, 1997

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pathology, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA/aff>

    Sara Contente, Kaylene Kenyon, Priya Sriraman, Savitri Subramanyan & Robert M. Friedman

Authors
  1. Sara Contente
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kaylene Kenyon
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Priya Sriraman
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Savitri Subramanyan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Robert M. Friedman
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Contente, S., Kenyon, K., Sriraman, P. et al. Epigenetic inhibition of lysyl oxidase transcription after transformation by ras oncogene. Mol Cell Biochem 194, 79–91 (1999). https://doi.org/10.1023/A:1006913122261

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1006913122261

Search

Navigation